BioSpace News Archive

Business

SmartPharm Therapeutics Appoints José Trevejo, MD, PhD, as Chief Executive Officer

SmartPharm Therapeutics announced that José Trevejo, MD, PhD, has been appointed Chief Executive Officer.

June 25, 2019
·
3 min read
FDA

Bausch Health Announces U.S. Launch of DUOBRII™ (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis in Adults

DUOBRII is the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation.

June 25, 2019
·
11 min read
Business

Nevro Announces Executive Appointments

Names Niamh Pellegrini as Chief Commercial Officer and Lori Ciano as Chief Human Resources Officer

June 25, 2019
·
3 min read
Business

Q² Solutions, HSBlox and R3 announce successful Proof-of-Concept of blockchain-based solution for tracking of Human Biological Samples in Clinical Research

Q2 Solutions, a leading global clinical trial laboratory services organization that helps customers achieve better clinical trial outcomes, conducted a sample tracking proof-of-concept using distributed ledger technology in partnership with HSBlox, Inc.

June 25, 2019
·
5 min read
Job Trends

Recondo Technology, Generating 16M Annual Patient Estimates, Issues Statement on Trump Administration’s Executive Order to Promote Healthcare Price Transparency

Industry leader with 12 years of experience in automated patient price estimates provides guidance on how hospitals can comply in a way that improves patient satisfaction and pre-service collections.

June 25, 2019
·
3 min read
Drug Development

Rodin Therapeutics Announces Positive Phase 1 Results Supporting Continued Development of RDN-929 for Treatment of Neurologic Diseases

Compound Designed to Enhance Synaptic Integrity and Improve Learning, Memory and Function

June 25, 2019
·
3 min read
Deals

Antibe Therapeutics Announces CEO Letter to Shareholders - June 25, 2019

Last year was pivotal for Antibe as we delivered dramatic gastrointestinal (“GI”) safety data for our lead drug, ATB-346, in a head-to-head Phase 2B study versus naproxen, the most prescribed NSAID in the United States.

June 25, 2019
·
7 min read
Deals

Flex Pharma Announces Broker Authority to Vote on Certain Proposals

Flex Pharma, Inc. announced that on or about June 27, 2019 it will mail a supplement to its proxy materials to provide stockholders with updated information regarding brokers’ discretionary authority to vote stockholders’ shares on Proposal 2 and Proposal 4.

June 25, 2019
·
7 min read
Deals

City of Hope Reveals Its Bold Vision to Invest More Than $1B for World-Class Cancer Care at FivePoint Gateway in Orange County

Recognizing immediate need, City of Hope accelerates plans to bring highly specialized cancer care, phase I-III clinical trials, and precision medicine and early detection to the nation’s sixth most populous county

June 25, 2019
·
9 min read
Deals

ArQule Announces Pricing of $90 Million Public Offering of Common Stock

ArQule, Inc. announced the pricing of an underwritten public offering of 9,250,000 shares of its common stock at a price to the public of $9.75 per share.

June 25, 2019
·
4 min read